Id |
Subject |
Object |
Predicate |
Lexical cue |
T774 |
11-38 |
Protein |
denotes |
of C-C Chemokine Receptor 5 |
T818 |
98-138 |
Positive_regulation |
denotes |
Upregulation of IL-1Ra in Melanoma Model |
T779 |
111-120 |
Protein |
denotes |
of IL-1Ra |
T773 |
224-271 |
Protein |
denotes |
C-C chemokine receptor type 5 (CCR5) expression |
T790 |
228-237 |
Protein |
denotes |
chemokine |
T787 |
247-260 |
Protein |
denotes |
type 5 (CCR5) |
T809 |
255-259 |
Protein |
denotes |
CCR5 |
T786 |
326-330 |
Protein |
denotes |
CCR5 |
T800 |
350-354 |
Protein |
denotes |
mice |
T796 |
350-383 |
Protein |
denotes |
mice and wild type (CCR5+/+) mice |
T794 |
393-397 |
Protein |
denotes |
mice |
T802 |
483-498 |
Protein |
denotes |
to CCR5+/+ mice |
T814 |
500-579 |
Positive_regulation |
denotes |
We investigated the activation of NF-κB since it is an implicated transcription |
T797 |
531-539 |
Protein |
denotes |
of NF-κB |
T817 |
590-664 |
Regulation |
denotes |
the regulation of genes involving cell growth, apoptosis, and tumor growth |
T778 |
605-664 |
Protein |
denotes |
of genes involving cell growth, apoptosis, and tumor growth |
T777 |
713-721 |
Protein |
denotes |
of NF-κB |
T775 |
744-747 |
Protein |
denotes |
p50 |
T791 |
752-755 |
Protein |
denotes |
p65 |
T780 |
761-772 |
Entity |
denotes |
the nucleus |
T801 |
867-871 |
Protein |
denotes |
mice |
T808 |
912-916 |
Protein |
denotes |
mice |
T810 |
918-923 |
Protein |
denotes |
NF-κB |
T782 |
941-948 |
Protein |
denotes |
protein |
T819 |
969-1001 |
Protein_catabolism |
denotes |
cleaved caspase-3, cleaved PARP, |
T795 |
969-1001 |
Protein |
denotes |
cleaved caspase-3, cleaved PARP, |
T805 |
996-1000 |
Protein |
denotes |
PARP |
T799 |
1006-1009 |
Protein |
denotes |
Bax |
T813 |
1046-1053 |
Protein |
denotes |
protein |
T816 |
1046-1064 |
Gene_expression |
denotes |
protein expression |
T811 |
1081-1086 |
Protein |
denotes |
Bcl-2 |
T806 |
1088-1095 |
Protein |
denotes |
C-IAP1, |
T812 |
1145-1149 |
Protein |
denotes |
mice |
T798 |
1193-1200 |
Protein |
denotes |
IL-1Ra, |
T804 |
1228-1237 |
Protein |
denotes |
cytokine, |
T793 |
1303-1307 |
Protein |
denotes |
mice |
T784 |
1333-1337 |
Protein |
denotes |
CCR5 |
T792 |
1341-1345 |
Protein |
denotes |
mice |
T776 |
1373-1394 |
Entity |
denotes |
CD8+ cytotoxic T cell |
T783 |
1399-1425 |
Entity |
denotes |
CD57+ natural killer cells |
T785 |
1501-1505 |
Protein |
denotes |
mice |
T789 |
1526-1530 |
Protein |
denotes |
CCR5 |
T803 |
1534-1538 |
Protein |
denotes |
mice |
T781 |
1577-1592 |
Protein |
denotes |
CCR5 deficiency |
T788 |
1655-1660 |
Protein |
denotes |
NF-κB |
T815 |
1665-1687 |
Positive_regulation |
denotes |
upregulation of IL-1Ra |
T807 |
1678-1687 |
Protein |
denotes |
of IL-1Ra |
T4332 |
1703-1713 |
Protein |
denotes |
Chemokines |
T4302 |
1718-1831 |
Entity |
denotes |
small soluble molecules that are best known for their potent ability to induce cancer cell growth by inflammation |
T4311 |
1844-1859 |
Entity |
denotes |
of cancer cells |
T4264 |
1868-1878 |
Protein |
denotes |
chemokines |
T4318 |
1883-1892 |
Protein |
denotes |
chemokine |
T4294 |
1883-1902 |
Protein |
denotes |
chemokine receptors |
T4299 |
1948-1989 |
Protein |
denotes |
the chemokine (C-C motif) ligand 5 (CCL5) |
T4228 |
1984-1988 |
Protein |
denotes |
CCL5 |
T4263 |
1994-2024 |
Protein |
denotes |
C-C chemokine receptor (CCR5), |
T4252 |
2018-2022 |
Protein |
denotes |
CCR5 |
T4238 |
2066-2084 |
Entity |
denotes |
inflammatory cells |
T4353 |
2172-2211 |
Gene_expression |
denotes |
Intermediate and strong CCR5 expression |
T4281 |
2196-2200 |
Protein |
denotes |
CCR5 |
T4265 |
2381-2406 |
Entity |
denotes |
prostate cancer cells [6] |
T4340 |
2408-2436 |
Gene_expression |
denotes |
Local production of the CCL5 |
T4248 |
2425-2436 |
Protein |
denotes |
of the CCL5 |
T4333 |
2552-2556 |
Protein |
denotes |
CCR5 |
T4362 |
2552-2567 |
Negative_regulation |
denotes |
CCR5 disruption |
T4285 |
2694-2701 |
Protein |
denotes |
of CCR5 |
T4260 |
2750-2754 |
Protein |
denotes |
CCR5 |
T4322 |
2750-2765 |
Entity |
denotes |
CCR5 inhibitors |
T4338 |
2841-2859 |
Entity |
denotes |
hepatoma cells [4] |
T4256 |
2907-2961 |
Protein |
denotes |
the deficiency of inflammatory chemokine receptor CCR5 |
T4324 |
2922-2947 |
Protein |
denotes |
of inflammatory chemokine |
T4230 |
2948-2956 |
Protein |
denotes |
receptor |
T4282 |
2978-3000 |
Protein |
denotes |
a suppressive receptor |
T4292 |
3075-3090 |
Protein |
denotes |
CCR5 deficiency |
T4259 |
3136-3208 |
Protein |
denotes |
Interleukin-1 receptor antagonist (IL-1Ra), a member of the IL-1 family, |
T4253 |
3159-3178 |
Entity |
denotes |
antagonist (IL-1Ra) |
T4309 |
3171-3177 |
Protein |
denotes |
IL-1Ra |
T4306 |
3189-3207 |
Protein |
denotes |
of the IL-1 family |
T4354 |
3212-3291 |
Negative_regulation |
denotes |
a naturally occurring cytokine that competitively blocks the IL-1 receptor [13] |
T4298 |
3212-3291 |
Protein |
denotes |
a naturally occurring cytokine that competitively blocks the IL-1 receptor [13] |
T4328 |
3269-3291 |
Protein |
denotes |
the IL-1 receptor [13] |
T4312 |
3273-3277 |
Protein |
denotes |
IL-1 |
T4327 |
3301-3307 |
Protein |
denotes |
IL-1Ra |
T4255 |
3482-3491 |
Protein |
denotes |
of IL-1Ra |
T4235 |
3520-3526 |
Protein |
denotes |
IL-1Ra |
T4351 |
3520-3537 |
Gene_expression |
denotes |
IL-1Ra expression |
T4345 |
3520-3601 |
Negative_regulation |
denotes |
IL-1Ra expression was reduced in prostate [14], breast [15], and skin cancer [16] |
T4278 |
3624-3661 |
Protein |
denotes |
that endogenous IL-1Ra deficient mice |
T4293 |
3640-3646 |
Protein |
denotes |
IL-1Ra |
T4274 |
3712-3728 |
Entity |
denotes |
carcinogens [17] |
T4232 |
3755-3814 |
Entity |
denotes |
of the melanoma cells that were transduced with IL-1Ra gene |
T4242 |
3803-3809 |
Protein |
denotes |
IL-1Ra |
T4254 |
3803-3814 |
Protein |
denotes |
IL-1Ra gene |
T4319 |
3868-3882 |
Protein |
denotes |
IL-1R blockade |
T4280 |
3959-3970 |
Protein |
denotes |
that IL-1Ra |
T4316 |
4010-4029 |
Entity |
denotes |
B16 melanoma growth |
T4301 |
4119-4123 |
Protein |
denotes |
IL-1 |
T4245 |
4119-4160 |
Protein |
denotes |
IL-1 knockout mice injected with melanoma |
T4290 |
4221-4228 |
Protein |
denotes |
IL-1Ra, |
T4244 |
4243-4255 |
Entity |
denotes |
temozolomide |
T4261 |
4260-4269 |
Entity |
denotes |
docetaxel |
T4291 |
4341-4372 |
Entity |
denotes |
B16 melanoma cells in vivo [25] |
T4307 |
4399-4405 |
Protein |
denotes |
IL-1Ra |
T4234 |
4449-4457 |
Protein |
denotes |
cytokine |
T4337 |
4459-4464 |
Protein |
denotes |
NF-κB |
T4284 |
4640-4672 |
Protein |
denotes |
Constitutive activation of NF-κB |
T4295 |
4811-4831 |
Protein |
denotes |
anti-apoptotic genes |
T4287 |
4894-4899 |
Protein |
denotes |
NF-κB |
T4251 |
4995-5003 |
Protein |
denotes |
on c-Rel |
T4275 |
5037-5042 |
Protein |
denotes |
c-Rel |
T4270 |
5060-5064 |
Protein |
denotes |
IL-2 |
T4233 |
5066-5070 |
Protein |
denotes |
IL-3 |
T4272 |
5072-5078 |
Protein |
denotes |
GM-CSF |
T4279 |
5084-5088 |
Protein |
denotes |
IFNγ |
T4342 |
5084-5099 |
Gene_expression |
denotes |
IFNγ expression |
T4250 |
5103-5121 |
Entity |
denotes |
T lymphocytes [30] |
T4283 |
5123-5143 |
Protein |
denotes |
C-Rel-deficient mice |
T4335 |
5186-5203 |
Protein |
denotes |
various cytokines |
T4268 |
5226-5233 |
Entity |
denotes |
T cells |
T4323 |
5238-5249 |
Entity |
denotes |
macrophages |
T4297 |
5330-5335 |
Protein |
denotes |
NF-κB |
T4331 |
5418-5488 |
Entity |
denotes |
apoptotic cancer cell death, (2) stimulating tumor killing lymphocytes |
T4350 |
5505-5563 |
Positive_regulation |
denotes |
(3) increasing the production of tumor killing lymphokines |
T4239 |
5505-5563 |
Entity |
denotes |
(3) increasing the production of tumor killing lymphokines |
T4360 |
5520-5563 |
Gene_expression |
denotes |
the production of tumor killing lymphokines |
T4243 |
5535-5563 |
Protein |
denotes |
of tumor killing lymphokines |
T4344 |
5565-5584 |
Positive_regulation |
denotes |
Activation of NF-κB |
T4336 |
5576-5584 |
Protein |
denotes |
of NF-κB |
T4339 |
5677-5744 |
Negative_regulation |
denotes |
that inhibition of NF-κB by dehydroxymethyl-epoxyquinomicin (DHMEQ) |
T4320 |
5693-5701 |
Protein |
denotes |
of NF-κB |
T4334 |
5702-5744 |
Entity |
denotes |
by dehydroxymethyl-epoxyquinomicin (DHMEQ) |
T4347 |
5796-5830 |
Negative_regulation |
denotes |
inhibition of CCR5 expression [32] |
T4343 |
5807-5825 |
Gene_expression |
denotes |
of CCR5 expression |
T4288 |
5810-5814 |
Protein |
denotes |
CCR5 |
T4357 |
5832-5851 |
Positive_regulation |
denotes |
Activation of NF-κB |
T4313 |
5843-5851 |
Protein |
denotes |
of NF-κB |
T4303 |
5867-5880 |
Protein |
denotes |
CCL5-mediated |
T4361 |
5958-5977 |
Negative_regulation |
denotes |
inhibition of NF-κB |
T4300 |
5969-5977 |
Protein |
denotes |
of NF-κB |
T4346 |
5996-6030 |
Regulation |
denotes |
in CCR5 mediated tumor development |
T4330 |
5996-6030 |
Protein |
denotes |
in CCR5 mediated tumor development |
T4247 |
6032-6037 |
Protein |
denotes |
NF-κB |
T4267 |
6032-6072 |
Entity |
denotes |
NF-κB transcription factor binding sites |
T4314 |
6088-6142 |
Entity |
denotes |
the promoter region of proinflammatory cytokine genes, |
T4304 |
6108-6142 |
Protein |
denotes |
of proinflammatory cytokine genes, |
T4241 |
6127-6135 |
Protein |
denotes |
cytokine |
T4317 |
6151-6160 |
Protein |
denotes |
IL-1alpha |
T4246 |
6162-6166 |
Protein |
denotes |
IL-6 |
T4271 |
6168-6174 |
Protein |
denotes |
GM-CSF |
T4273 |
6180-6182 |
Protein |
denotes |
KC |
T4276 |
6208-6218 |
Protein |
denotes |
the IL-1Ra |
T4326 |
6319-6328 |
Protein |
denotes |
of IL-1Ra |
T4258 |
6372-6376 |
Protein |
denotes |
IL-1 |
T4352 |
6406-6446 |
Regulation |
denotes |
the regulation of IL-1Ra gene expression |
T4355 |
6421-6446 |
Gene_expression |
denotes |
of IL-1Ra gene expression |
T4289 |
6424-6430 |
Protein |
denotes |
IL-1Ra |
T4321 |
6493-6533 |
Protein |
denotes |
of three different transcription factors |
T4325 |
6535-6582 |
Entity |
denotes |
NF-κB/PU.1/GA-binding protein binding site [35] |
T4356 |
6584-6671 |
Positive_regulation |
denotes |
Nuclear translocation of NF-κB (p65) was significantly enhanced and prolonged in IL-1Ra |
T4349 |
6584-6671 |
Regulation |
denotes |
Nuclear translocation of NF-κB (p65) was significantly enhanced and prolonged in IL-1Ra |
T4315 |
6606-6620 |
Protein |
denotes |
of NF-κB (p65) |
T4305 |
6616-6619 |
Protein |
denotes |
p65 |
T4308 |
6665-6671 |
Protein |
denotes |
IL-1Ra |
T4266 |
6682-6686 |
Protein |
denotes |
mice |
T4229 |
6708-6727 |
Protein |
denotes |
wild type mice [36] |
T4237 |
6729-6760 |
Protein |
denotes |
Intracellular IL-1Ra (icIL-1Ra) |
T4329 |
6751-6759 |
Protein |
denotes |
icIL-1Ra |
T4341 |
6774-6786 |
Negative_regulation |
denotes |
inhibit IL-1 |
T4231 |
6782-6786 |
Protein |
denotes |
IL-1 |
T4358 |
6790-6804 |
Negative_regulation |
denotes |
blocking NF-κB |
T4269 |
6799-6804 |
Protein |
denotes |
NF-κB |
T4286 |
6874-6878 |
Protein |
denotes |
IL-1 |
T4359 |
6911-6935 |
Positive_regulation |
denotes |
of NF-κB activation [38] |
T4296 |
6914-6919 |
Protein |
denotes |
NF-κB |
T4348 |
6958-6982 |
Gene_expression |
denotes |
the expression of IL-1Ra |
T4249 |
6973-6982 |
Protein |
denotes |
of IL-1Ra |
T4240 |
7065-7070 |
Protein |
denotes |
NF-κB |
T4257 |
7143-7148 |
Protein |
denotes |
NF-κB |
T4262 |
7153-7159 |
Protein |
denotes |
IL-1Ra |
T4277 |
7167-7176 |
Protein |
denotes |
chemokine |
T4310 |
7167-7199 |
Protein |
denotes |
chemokine receptor CCR5-mediated |
T4236 |
7167-7199 |
Protein |
denotes |
chemokine receptor CCR5-mediated |
T5332 |
7279-7291 |
Protein |
denotes |
CCR5−/− Mice |
T5329 |
7303-7310 |
Protein |
denotes |
of CCR5 |
T5343 |
7375-7379 |
Protein |
denotes |
mice |
T5344 |
7381-7402 |
Entity |
denotes |
B16-F0 melanoma cells |
T5347 |
7459-7463 |
Protein |
denotes |
mice |
T5348 |
7465-7469 |
Entity |
denotes |
n = |
T5330 |
7530-7546 |
Protein |
denotes |
the CCR5−/− mice |
T5340 |
7584-7600 |
Protein |
denotes |
the CCR5+/+ mice |
T5342 |
7622-7638 |
Protein |
denotes |
the CCR5−/− mice |
T5327 |
7689-7697 |
Protein |
denotes |
the CCR5 |
T5326 |
7701-7705 |
Protein |
denotes |
mice |
T5341 |
7854-7858 |
Protein |
denotes |
mice |
T5349 |
7944-7971 |
Protein |
denotes |
mice (75% of starting time) |
T5324 |
7976-7994 |
Protein |
denotes |
CCR5+/+ mice (15%) |
T5339 |
8098-8110 |
Protein |
denotes |
CCR5−/− mice |
T5325 |
8115-8127 |
Protein |
denotes |
CCR5+/+ mice |
T5338 |
8170-8191 |
Protein |
denotes |
CCR5−/− mice survived |
T5336 |
8198-8235 |
Protein |
denotes |
only 15% of the CCR5+/+ mice survived |
T5345 |
8207-8235 |
Protein |
denotes |
of the CCR5+/+ mice survived |
T5335 |
8277-8296 |
Protein |
denotes |
the sacrificed mice |
T5333 |
8401-8428 |
Entity |
denotes |
proliferation antigen PCNA, |
T5323 |
8401-8428 |
Protein |
denotes |
proliferation antigen PCNA, |
T5331 |
8489-8493 |
Protein |
denotes |
mice |
T5328 |
8571-8620 |
Protein |
denotes |
of the CCR5−/− mice, but not those of the CCR5+/+ |
T5350 |
8621-8626 |
Protein |
denotes |
mice, |
T5337 |
8662-8666 |
Protein |
denotes |
PCNA |
T5334 |
8662-8681 |
Entity |
denotes |
PCNA reactive cells |
T5346 |
8724-8740 |
Protein |
denotes |
mice (Figure 1E) |
T17675 |
8821-8833 |
Protein |
denotes |
CCR5−/− mice |
T17677 |
8835-8838 |
Protein |
denotes |
A–C |
T17672 |
8876-8914 |
Entity |
denotes |
B16 melanoma cells (5×105 cells/mouse) |
T17683 |
8941-8970 |
Protein |
denotes |
CCR5+/+ mice and CCR5−/− mice |
T17685 |
8949-8953 |
Protein |
denotes |
mice |
T17676 |
8972-8976 |
Entity |
denotes |
n = |
T17684 |
9082-9098 |
Protein |
denotes |
The CCR5−/− mice |
T17678 |
9166-9181 |
Protein |
denotes |
to CCR5+/+ mice |
T17680 |
9212-9221 |
Protein |
denotes |
mean ± SD |
T17679 |
9263-9284 |
Protein |
denotes |
CCR5+/+ mice (P<0.05) |
T17686 |
9301-9305 |
Protein |
denotes |
mice |
T17682 |
9364-9398 |
Protein |
denotes |
to CCR5+/+ mice (by Log-rank Test) |
T17687 |
9449-9504 |
Gene_expression |
denotes |
expression of proliferating cell nuclear antigen (PCNA) |
T17673 |
9460-9504 |
Protein |
denotes |
of proliferating cell nuclear antigen (PCNA) |
T17681 |
9499-9503 |
Protein |
denotes |
PCNA |
T17671 |
9547-9580 |
Entity |
denotes |
S.D. of four experimental animals |
T17674 |
9622-9643 |
Protein |
denotes |
CCR5+/+ mice (P<0.05) |
T18161 |
9672-9725 |
Negative_regulation |
denotes |
Decrease of NF-κB Activity in Tumor Tissue of CCR5−/− |
T5902 |
9672-9725 |
Negative_regulation |
denotes |
Decrease of NF-κB Activity in Tumor Tissue of CCR5−/− |
T18152 |
9684-9689 |
Protein |
denotes |
NF-κB |
T5893 |
9684-9689 |
Protein |
denotes |
NF-κB |
T18147 |
9726-9730 |
Protein |
denotes |
Mice |
T5884 |
9726-9730 |
Protein |
denotes |
Mice |
T5899 |
9731-9754 |
Positive_regulation |
denotes |
The activation of NF-κB |
T5892 |
9746-9754 |
Protein |
denotes |
of NF-κB |
T5896 |
9780-9801 |
Entity |
denotes |
cancer cell survival, |
T5885 |
9813-9834 |
Entity |
denotes |
melanoma cancer cells |
T5887 |
9842-9846 |
Protein |
denotes |
CCR5 |
T5900 |
9842-9857 |
Gene_expression |
denotes |
CCR5 expression |
T5903 |
9917-9954 |
Negative_regulation |
denotes |
the inactivation of NF-κB in melanoma |
T5897 |
9934-9942 |
Protein |
denotes |
of NF-κB |
T5890 |
9981-9989 |
Protein |
denotes |
of NF-κB |
T5886 |
10140-10144 |
Protein |
denotes |
mice |
T5901 |
10181-10321 |
Negative_regulation |
denotes |
the translocation of p50 and p-p65 into the nucleus through the inhibition of phosphorylation of IκB was also prevented in the tumor tissues |
T5898 |
10202-10205 |
Protein |
denotes |
p50 |
T5889 |
10210-10215 |
Protein |
denotes |
p-p65 |
T5891 |
10221-10232 |
Entity |
denotes |
the nucleus |
T5894 |
10333-10349 |
Protein |
denotes |
mice (Figure 2B) |
T5895 |
10437-10440 |
Protein |
denotes |
p50 |
T5888 |
10487-10503 |
Protein |
denotes |
mice (Figure 2C) |
T18159 |
10676-10699 |
Entity |
denotes |
extracts of the CCR5−/− |
T18151 |
10700-10704 |
Protein |
denotes |
mice |
T18153 |
10709-10721 |
Protein |
denotes |
CCR5+/+ mice |
T18162 |
10782-10799 |
Gene_expression |
denotes |
Expression of p50 |
T18158 |
10793-10799 |
Protein |
denotes |
of p50 |
T18149 |
10804-10807 |
Protein |
denotes |
p65 |
T18163 |
10804-10849 |
Phosphorylation |
denotes |
p65 phosphorylation in nuclear extracts (NE), |
T18148 |
10827-10848 |
Entity |
denotes |
nuclear extracts (NE) |
T18155 |
10885-10896 |
Entity |
denotes |
the cytosol |
T18160 |
10966-10972 |
Protein |
denotes |
of p50 |
T18157 |
11028-11031 |
Protein |
denotes |
p50 |
T18156 |
11079-11083 |
Protein |
denotes |
mice |
T18150 |
11102-11135 |
Entity |
denotes |
S.D. of four experimental animals |
T18154 |
11177-11198 |
Protein |
denotes |
CCR5+/+ mice (p<0.05) |
T6415 |
11266-11330 |
Negative_regulation |
denotes |
Inhibition of the Expression of Anti-apoptotic Proteins in CCR5− |
T6408 |
11303-11330 |
Protein |
denotes |
apoptotic Proteins in CCR5− |
T6399 |
11333-11337 |
Protein |
denotes |
Mice |
T6413 |
11353-11381 |
Negative_regulation |
denotes |
inhibition of NF-κB activity |
T6396 |
11367-11372 |
Protein |
denotes |
NF-κB |
T6414 |
11542-11596 |
Gene_expression |
denotes |
expression of apoptotic cell death regulatory proteins |
T6398 |
11553-11596 |
Protein |
denotes |
of apoptotic cell death regulatory proteins |
T6404 |
11689-11701 |
Protein |
denotes |
CCR5−/− mice |
T6403 |
11728-11742 |
Entity |
denotes |
melanoma cells |
T6410 |
11814-11851 |
Protein |
denotes |
the tumor tissues of the CCR5−/− mice |
T6412 |
11814-11852 |
Localization |
denotes |
the tumor tissues of the CCR5−/− mice |
T6395 |
11865-11893 |
Protein |
denotes |
the CCR5+/+ mice (Figure 3A) |
T6397 |
11973-11982 |
Protein |
denotes |
caspase-3 |
T6405 |
11987-11990 |
Protein |
denotes |
Bax |
T6411 |
12033-12037 |
Protein |
denotes |
mice |
T6401 |
12046-12081 |
Protein |
denotes |
the CCR5+/+ mice (Figure 3B and 3C) |
T6406 |
12151-12168 |
Protein |
denotes |
of tumor proteins |
T6394 |
12194-12241 |
Protein |
denotes |
levels of cleaved caspase-3, cleaved caspase-9, |
T6400 |
12231-12240 |
Protein |
denotes |
caspase-9 |
T6409 |
12250-12254 |
Protein |
denotes |
PARP |
T6407 |
12259-12262 |
Protein |
denotes |
Bax |
T6392 |
12286-12291 |
Protein |
denotes |
Bcl-2 |
T6402 |
12296-12302 |
Protein |
denotes |
C-IAP1 |
T6393 |
12343-12347 |
Protein |
denotes |
mice |
T18555 |
12450-12480 |
Localization |
denotes |
tumor tissues of CCR5 −/− mice |
T18545 |
12450-12480 |
Protein |
denotes |
tumor tissues of CCR5 −/− mice |
T18546 |
12464-12471 |
Protein |
denotes |
of CCR5 |
T18538 |
12495-12500 |
Entity |
denotes |
cells |
T18527 |
12566-12570 |
Entity |
denotes |
DAPI |
T18537 |
12677-12692 |
Entity |
denotes |
of DAPI-stained |
T18544 |
12694-12724 |
Entity |
denotes |
TUNEL-positive cells that were |
T18540 |
12756-12789 |
Protein |
denotes |
S.D. of four experimental animals |
T18539 |
12846-12858 |
Protein |
denotes |
CCR5+/+ mice |
T18535 |
12896-12941 |
Protein |
denotes |
Apoptotic protein (cleaved caspase-3 and Bax) |
T18525 |
12923-12932 |
Protein |
denotes |
caspase-3 |
T18543 |
12937-12940 |
Protein |
denotes |
Bax |
T18532 |
13057-13134 |
Entity |
denotes |
of DAPI-stained, Specific antibody (cleaved caspase-3 and Bax)-positive cells |
T18536 |
13060-13072 |
Entity |
denotes |
DAPI-stained |
T18553 |
13083-13119 |
Entity |
denotes |
antibody (cleaved caspase-3 and Bax) |
T18552 |
13101-13110 |
Protein |
denotes |
caspase-3 |
T18533 |
13115-13118 |
Protein |
denotes |
Bax |
T18547 |
13176-13209 |
Protein |
denotes |
S.D. of four experimental animals |
T18551 |
13266-13278 |
Protein |
denotes |
CCR5+/+ mice |
T18554 |
13310-13346 |
Gene_expression |
denotes |
The expression of apoptotic proteins |
T18530 |
13325-13346 |
Protein |
denotes |
of apoptotic proteins |
T18549 |
13386-13405 |
Entity |
denotes |
specific antibodies |
T18534 |
13415-13444 |
Protein |
denotes |
caspase-3, cleaved caspase-9, |
T18542 |
13434-13443 |
Protein |
denotes |
caspase-9 |
T18529 |
13453-13457 |
Protein |
denotes |
PARP |
T18526 |
13459-13462 |
Protein |
denotes |
Bax |
T18541 |
13464-13469 |
Protein |
denotes |
Bcl-2 |
T18548 |
13474-13480 |
Protein |
denotes |
c-IAP1 |
T18524 |
13503-13522 |
Protein |
denotes |
The β-actin protein |
T18550 |
13503-13522 |
Protein |
denotes |
The β-actin protein |
T18528 |
13644-13678 |
Entity |
denotes |
S.D. of three experimental animals |
T18531 |
13720-13741 |
Protein |
denotes |
CCR5+/+ mice (p<0.05) |
T19295 |
13744-13799 |
Positive_regulation |
denotes |
Upregulation of IL-1Ra in the Tumor and Spleen of CCR5− |
T7227 |
13744-13806 |
Positive_regulation |
denotes |
Upregulation of IL-1Ra in the Tumor and Spleen of CCR5−/− Mice |
T19293 |
13757-13766 |
Protein |
denotes |
of IL-1Ra |
T7223 |
13757-13766 |
Protein |
denotes |
of IL-1Ra |
T19286 |
13770-13799 |
Protein |
denotes |
the Tumor and Spleen of CCR5− |
T7212 |
13794-13806 |
Protein |
denotes |
CCR5−/− Mice |
T19288 |
13802-13806 |
Protein |
denotes |
Mice |
T7219 |
13840-13852 |
Protein |
denotes |
the cytokine |
T7214 |
13924-13928 |
Protein |
denotes |
mice |
T7218 |
13943-14006 |
Protein |
denotes |
a cytokine array assay using a Mouse Proteome Array (Figure 4A) |
T7208 |
14024-14056 |
Protein |
denotes |
cytokines, the levels of IL-1Ra, |
T7217 |
14049-14055 |
Protein |
denotes |
IL-1Ra |
T7220 |
14057-14061 |
Protein |
denotes |
MIG, |
T7207 |
14057-14068 |
Protein |
denotes |
MIG, MIP-1α |
T7224 |
14129-14133 |
Protein |
denotes |
mice |
T7206 |
14154-14158 |
Protein |
denotes |
mice |
T7211 |
14182-14200 |
Protein |
denotes |
no other cytokines |
T7213 |
14236-14252 |
Protein |
denotes |
the CCR5−/− mice |
T7210 |
14257-14285 |
Protein |
denotes |
the CCR5+/+ mice (Figure 4B) |
T7221 |
14345-14372 |
Protein |
denotes |
of CCR5−/− mice (Figure 4C) |
T7209 |
14384-14390 |
Protein |
denotes |
IL-1Ra |
T7226 |
14434-14533 |
Gene_expression |
denotes |
the expression of IL-1Ra in tumor and spleen tissues was analyzed by immunofluorescence and western |
T7216 |
14449-14458 |
Protein |
denotes |
of IL-1Ra |
T7228 |
14544-14568 |
Gene_expression |
denotes |
The expression of IL-1Ra |
T7225 |
14544-14627 |
Positive_regulation |
denotes |
The expression of IL-1Ra was upregulated in tumor and spleen tissues of the CCR5−/− |
T7215 |
14559-14568 |
Protein |
denotes |
of IL-1Ra |
T7222 |
14628-14632 |
Protein |
denotes |
mice |
T19268 |
14779-14817 |
Protein |
denotes |
mouse cytokine array panel coordinates |
T19292 |
14819-14833 |
Entity |
denotes |
Nitrocellulose |
T19281 |
14819-14843 |
Entity |
denotes |
Nitrocellulose membranes |
T19275 |
14855-14889 |
Entity |
denotes |
different anti-cytokine antibodies |
T19278 |
14921-14941 |
Protein |
denotes |
cytokine array panel |
T19297 |
14951-15030 |
Gene_expression |
denotes |
the cytokine expression difference in tumor tissues of CCR5+/+ mice and CCR5−/− |
T19267 |
14955-14963 |
Protein |
denotes |
cytokine |
T19283 |
15006-15018 |
Protein |
denotes |
CCR5+/+ mice |
T19269 |
15031-15036 |
Protein |
denotes |
mice, |
T19279 |
15031-15054 |
Entity |
denotes |
mice, especially IL-1Ra |
T19271 |
15200-15212 |
Entity |
denotes |
the membrane |
T19276 |
15214-15238 |
Protein |
denotes |
C, Protein immune-arrays |
T19294 |
15260-15298 |
Protein |
denotes |
Mouse cytokine array in spleen tissues |
T19291 |
15326-15335 |
Protein |
denotes |
cytokines |
T19289 |
15344-15374 |
Protein |
denotes |
CCR5+/+ mice and CCR5−/− mice, |
T19282 |
15352-15356 |
Protein |
denotes |
mice |
T19270 |
15538-15550 |
Entity |
denotes |
the membrane |
T19290 |
15637-15643 |
Protein |
denotes |
IL-1Ra |
T19277 |
15727-15774 |
Protein |
denotes |
of DAPI-stained, IL-1Ra antibody-positive cells |
T19274 |
15730-15742 |
Entity |
denotes |
DAPI-stained |
T19280 |
15751-15759 |
Protein |
denotes |
antibody |
T19273 |
15816-15849 |
Entity |
denotes |
S.D. of four experimental animals |
T19287 |
15906-15918 |
Protein |
denotes |
CCR5+/+ mice |
T19296 |
15956-16037 |
Gene_expression |
denotes |
Expression of IL-1Ra was analyzed by western blotting in tumor and spleen tissues |
T19272 |
15967-15976 |
Protein |
denotes |
of IL-1Ra |
T19284 |
16127-16161 |
Entity |
denotes |
S.D. of three experimental animals |
T19285 |
16203-16224 |
Protein |
denotes |
CCR5+/+ mice (p<0.05) |
T8653 |
16240-16243 |
Protein |
denotes |
CD8 |
T8612 |
16240-16251 |
Entity |
denotes |
CD8 T cells |
T8633 |
16256-16263 |
Entity |
denotes |
NK Cell |
T8636 |
16282-16314 |
Protein |
denotes |
Tumor and Spleen of CCR5−/− Mice |
T8637 |
16372-16384 |
Protein |
denotes |
CCR5−/− mice |
T8668 |
16473-16494 |
Entity |
denotes |
CD8+ cytotoxic T cell |
T8634 |
16499-16553 |
Entity |
denotes |
CD57+ Natural Killer cells in tumor and spleen tissues |
T8667 |
16591-16603 |
Protein |
denotes |
CCR5−/− mice |
T8666 |
16653-16663 |
Entity |
denotes |
CD8+ cells |
T8669 |
16680-16753 |
Binding |
denotes |
as well as an increase in the number of infiltrating NK cells (Figure 5A) |
T8627 |
16733-16753 |
Entity |
denotes |
NK cells (Figure 5A) |
T8635 |
16755-16767 |
Entity |
denotes |
CD8+ T cells |
T8671 |
16755-16839 |
Binding |
denotes |
CD8+ T cells and CD57+ NK cells were spread diffusely throughout the entire sections |
T8658 |
16772-16786 |
Entity |
denotes |
CD57+ NK cells |
T8646 |
16895-16910 |
Entity |
denotes |
of CD8+ T cells |
T8652 |
16915-16929 |
Entity |
denotes |
CD57+ NK cells |
T8659 |
16938-16950 |
Protein |
denotes |
CCR5+/+ mice |
T8643 |
16955-16960 |
Protein |
denotes |
CCR5− |
T8670 |
16961-16994 |
Localization |
denotes |
− mice in immunity-related organ, |
T8618 |
16961-16994 |
Protein |
denotes |
− mice in immunity-related organ, |
T8611 |
17012-17019 |
Protein |
denotes |
the CD8 |
T8632 |
17024-17028 |
Protein |
denotes |
CD57 |
T8625 |
17080-17095 |
Entity |
denotes |
of CD8+ T cells |
T8623 |
17100-17114 |
Entity |
denotes |
CD57+ NK cells |
T8631 |
17156-17160 |
Protein |
denotes |
mice |
T8638 |
17180-17199 |
Protein |
denotes |
of the CCR5+/+ mice |
T8639 |
17270-17273 |
Protein |
denotes |
CD8 |
T8622 |
17270-17281 |
Entity |
denotes |
CD8 T cells |
T8624 |
17286-17294 |
Entity |
denotes |
NK cells |
T8641 |
17313-17322 |
Entity |
denotes |
cytotoxic |
T8651 |
17390-17402 |
Protein |
denotes |
CCR5−/− mice |
T19901 |
17481-17493 |
Entity |
denotes |
CD8+ T cells |
T19905 |
17498-17506 |
Entity |
denotes |
NK cells |
T19902 |
17553-17557 |
Protein |
denotes |
mice |
T19903 |
17644-17686 |
Protein |
denotes |
CD8 (CD8+ cytotoxic T-cell surface marker) |
T19897 |
17649-17685 |
Entity |
denotes |
CD8+ cytotoxic T-cell surface marker |
T19896 |
17649-17685 |
Entity |
denotes |
CD8+ cytotoxic T-cell surface marker |
T19894 |
17649-17685 |
Entity |
denotes |
CD8+ cytotoxic T-cell surface marker |
T19900 |
17697-17704 |
Entity |
denotes |
NK cell |
T19904 |
17898-17922 |
Entity |
denotes |
of lymphocyte phenotypes |
T19895 |
18043-18067 |
Protein |
denotes |
FACSAria flow cytometry, |
T19899 |
18047-18051 |
Protein |
denotes |
Aria |
T19898 |
18116-18149 |
Entity |
denotes |
S.D. of four experimental animals |
T8616 |
18162-18198 |
Entity |
denotes |
the cell phenotype change in CCR5−/− |
T8649 |
18199-18203 |
Protein |
denotes |
mice |
T8642 |
18208-18257 |
Protein |
denotes |
CCR5+/+ mice by inoculation of the melanoma cell, |
T8629 |
18236-18256 |
Entity |
denotes |
of the melanoma cell |
T8621 |
18258-18269 |
Entity |
denotes |
lymphocytes |
T8644 |
18326-18329 |
Protein |
denotes |
CD3 |
T8610 |
18326-18331 |
Entity |
denotes |
CD3 T |
T8606 |
18333-18336 |
Protein |
denotes |
CD4 |
T8626 |
18333-18338 |
Entity |
denotes |
CD4 T |
T8608 |
18343-18346 |
Entity |
denotes |
8 T |
T8665 |
18351-18358 |
Entity |
denotes |
NK cell |
T8647 |
18378-18382 |
Protein |
denotes |
mice |
T8630 |
18491-18503 |
Protein |
denotes |
3.1% of CCR5 |
T8640 |
18507-18523 |
Protein |
denotes |
mice (Figure 5C) |
T8619 |
18525-18589 |
Entity |
denotes |
The lymphocytes that infiltrated the tumor tissue of the CCR5−/− |
T8656 |
18590-18594 |
Protein |
denotes |
mice |
T8655 |
18621-18636 |
Protein |
denotes |
CD19, CD3, CD4, |
T8660 |
18621-18640 |
Protein |
denotes |
CD19, CD3, CD4, CD8 |
T8663 |
18627-18631 |
Protein |
denotes |
CD3, |
T8620 |
18627-18635 |
Protein |
denotes |
CD3, CD4 |
T8654 |
18664-18683 |
Protein |
denotes |
to the CCR5+/+ mice |
T8657 |
18692-18695 |
Protein |
denotes |
CD3 |
T8628 |
18692-18697 |
Entity |
denotes |
CD3 T |
T8661 |
18699-18702 |
Protein |
denotes |
CD4 |
T8648 |
18699-18704 |
Entity |
denotes |
CD4 T |
T8617 |
18711-18712 |
Entity |
denotes |
T |
T8615 |
18717-18747 |
Entity |
denotes |
NK cell portion of the CCR5−/− |
T8609 |
18748-18752 |
Protein |
denotes |
mice |
T8664 |
18854-18890 |
Protein |
denotes |
3.9% of the CCR5+/+ mice (Figure 5D) |
T8607 |
18859-18890 |
Protein |
denotes |
of the CCR5+/+ mice (Figure 5D) |
T8614 |
18949-18952 |
Protein |
denotes |
CD8 |
T8650 |
18949-18960 |
Entity |
denotes |
CD8 T cells |
T8645 |
18965-18973 |
Entity |
denotes |
NK cells |
T8613 |
18992-19001 |
Entity |
denotes |
cytotoxic |
T8662 |
19079-19091 |
Protein |
denotes |
CCR5−/− mice |
T11573 |
19198-19202 |
Protein |
denotes |
mice |
T11668 |
19212-19285 |
Protein |
denotes |
to the CCR5+/+ mice inoculated with B16 melanoma cells (Figure 1A and 1B) |
T11616 |
19243-19285 |
Entity |
denotes |
with B16 melanoma cells (Figure 1A and 1B) |
T11605 |
19330-19334 |
Protein |
denotes |
mice |
T11676 |
19373-19403 |
Positive_regulation |
denotes |
constitutively activated NF-κB |
T11622 |
19373-19403 |
Protein |
denotes |
constitutively activated NF-κB |
T11614 |
19418-19427 |
Protein |
denotes |
of IL-1Ra |
T11634 |
19520-19535 |
Protein |
denotes |
of NF-κB target |
T11592 |
19592-19616 |
Protein |
denotes |
genes (Bcl-2 and C-IAP1) |
T11620 |
19599-19604 |
Protein |
denotes |
Bcl-2 |
T11503 |
19609-19615 |
Protein |
denotes |
C-IAP1 |
T11589 |
19663-19678 |
Protein |
denotes |
apoptotic genes |
T11594 |
19688-19697 |
Protein |
denotes |
caspase-3 |
T11505 |
19709-19712 |
Protein |
denotes |
Bax |
T11523 |
19768-19822 |
Entity |
denotes |
of cytotoxic CD8+ T cells, CD57+ natural killer cells, |
T11522 |
19771-19780 |
Entity |
denotes |
cytotoxic |
T11626 |
19795-19821 |
Entity |
denotes |
CD57+ natural killer cells |
T11652 |
19841-19847 |
Protein |
denotes |
IL-1Ra |
T11574 |
19942-19959 |
Protein |
denotes |
the CCR5−/− mice, |
T11584 |
19983-19992 |
Protein |
denotes |
of IL-1Ra |
T11646 |
20011-20027 |
Protein |
denotes |
decreased NF-κB, |
T11537 |
20083-20095 |
Protein |
denotes |
CCR5−/− mice |
T11631 |
20097-20102 |
Protein |
denotes |
NF-κB |
T11669 |
20097-20218 |
Regulation |
denotes |
NF-κB regulates the expression of over 200 genes that control the immune system, cancer cell growth and inflammation [39] |
T11671 |
20113-20218 |
Gene_expression |
denotes |
the expression of over 200 genes that control the immune system, cancer cell growth and inflammation [39] |
T11600 |
20128-20218 |
Protein |
denotes |
of over 200 genes that control the immune system, cancer cell growth and inflammation [39] |
T11607 |
20330-20334 |
Entity |
denotes |
core |
T11525 |
20386-20391 |
Protein |
denotes |
NF-κB |
T11617 |
20446-20465 |
Protein |
denotes |
cytokine-associated |
T11560 |
20512-20559 |
Protein |
denotes |
the melanoma tumor tissues of the CCR5−/− mice, |
T11686 |
20512-20559 |
Localization |
denotes |
the melanoma tumor tissues of the CCR5−/− mice, |
T11688 |
20560-20583 |
Gene_expression |
denotes |
the expression of NF-κB |
T11547 |
20560-20674 |
Entity |
denotes |
the expression of NF-κB target cell death genes (Bax, caspase-3 and 9) and the DNA binding activity of NF-κB, were |
T11550 |
20575-20583 |
Protein |
denotes |
of NF-κB |
T11649 |
20602-20630 |
Protein |
denotes |
genes (Bax, caspase-3 and 9) |
T11625 |
20609-20612 |
Protein |
denotes |
Bax |
T11628 |
20614-20623 |
Protein |
denotes |
caspase-3 |
T11632 |
20660-20668 |
Protein |
denotes |
of NF-κB |
T11693 |
20704-20786 |
Gene_expression |
denotes |
the expression of cell death inhibitory NF-κB target genes, such as Bcl-2 and cIAP |
T11554 |
20719-20786 |
Protein |
denotes |
of cell death inhibitory NF-κB target genes, such as Bcl-2 and cIAP |
T11516 |
20744-20749 |
Protein |
denotes |
NF-κB |
T11557 |
20750-20771 |
Protein |
denotes |
target genes, such as |
T11613 |
20772-20777 |
Protein |
denotes |
Bcl-2 |
T11604 |
20896-20903 |
Protein |
denotes |
the p50 |
T11545 |
20908-20911 |
Protein |
denotes |
p65 |
T11577 |
20931-20942 |
Entity |
denotes |
the nucleus |
T11606 |
21016-21027 |
Protein |
denotes |
NF-κB [40], |
T11562 |
21118-21123 |
Protein |
denotes |
NF-κB |
T11675 |
21137-21167 |
Gene_expression |
denotes |
the expression of target genes |
T11635 |
21152-21167 |
Protein |
denotes |
of target genes |
T11667 |
21226-21230 |
Protein |
denotes |
mice |
T11542 |
21300-21305 |
Protein |
denotes |
NF-κB |
T11672 |
21324-21380 |
Positive_regulation |
denotes |
that NF-κB is activated or inactivated by many cytokines |
T11694 |
21324-21380 |
Negative_regulation |
denotes |
that NF-κB is activated or inactivated by many cytokines |
T11603 |
21329-21334 |
Protein |
denotes |
NF-κB |
T11638 |
21363-21380 |
Protein |
denotes |
by many cytokines |
T11586 |
21411-21419 |
Protein |
denotes |
cytokine |
T11684 |
21443-21459 |
Regulation |
denotes |
regulating NF-κB |
T11564 |
21454-21459 |
Protein |
denotes |
NF-κB |
T11610 |
21474-21515 |
Protein |
denotes |
cytokines, including IL-1, IL-6 and IL-8, |
T11658 |
21495-21499 |
Protein |
denotes |
IL-1 |
T11659 |
21501-21505 |
Protein |
denotes |
IL-6 |
T11541 |
21510-21514 |
Protein |
denotes |
IL-8 |
T11624 |
21525-21559 |
Protein |
denotes |
NF-κB pathways in tumor cells [41] |
T11529 |
21543-21559 |
Entity |
denotes |
tumor cells [41] |
T11536 |
21561-21587 |
Protein |
denotes |
The interleukin 10 (IL-10) |
T11500 |
21581-21586 |
Protein |
denotes |
IL-10 |
T11650 |
21637-21675 |
Entity |
denotes |
an anti-inflammatory factor [42], [43] |
T11524 |
21677-21682 |
Protein |
denotes |
IL-10 |
T11670 |
21707-21722 |
Positive_regulation |
denotes |
activated NF-κB |
T11657 |
21707-21722 |
Protein |
denotes |
activated NF-κB |
T11683 |
21760-21792 |
Negative_regulation |
denotes |
Inhibition of NF-κB by the IL-10 |
T11637 |
21771-21779 |
Protein |
denotes |
of NF-κB |
T11598 |
21780-21792 |
Protein |
denotes |
by the IL-10 |
T11655 |
21857-21866 |
Protein |
denotes |
caspase-3 |
T11546 |
21884-21909 |
Protein |
denotes |
Colon26-bearing mice [43] |
T11551 |
21968-21977 |
Protein |
denotes |
of IL-1Ra |
T11543 |
22021-22030 |
Protein |
denotes |
IL-1 [46] |
T11654 |
22058-22062 |
Protein |
denotes |
IL-1 |
T11687 |
22058-22151 |
Positive_regulation |
denotes |
IL-1 induces the activation of NF-κB in several cancers, and increases cell cycle progression |
T11690 |
22071-22094 |
Positive_regulation |
denotes |
the activation of NF-κB |
T11629 |
22086-22094 |
Protein |
denotes |
of NF-κB |
T11587 |
22312-22321 |
Protein |
denotes |
of IL-1Ra |
T11519 |
22364-22368 |
Protein |
denotes |
IL-1 |
T11501 |
22427-22434 |
Protein |
denotes |
of IL-1 |
T11662 |
22453-22463 |
Entity |
denotes |
antagonist |
T11673 |
22515-22546 |
Negative_regulation |
denotes |
dysregulation of IL-1 signaling |
T11679 |
22529-22546 |
Positive_regulation |
denotes |
of IL-1 signaling |
T11569 |
22532-22536 |
Protein |
denotes |
IL-1 |
T11623 |
22592-22618 |
Entity |
denotes |
of the receptor antagonist |
T11661 |
22599-22607 |
Protein |
denotes |
receptor |
T11499 |
22658-22662 |
Protein |
denotes |
IL-1 |
T11674 |
22658-22672 |
Positive_regulation |
denotes |
IL-1 signaling |
T11680 |
22723-22784 |
Gene_expression |
denotes |
The elevated expression of IL-1Ra, without any change of IL-1 |
T11602 |
22747-22756 |
Protein |
denotes |
of IL-1Ra |
T11644 |
22777-22784 |
Protein |
denotes |
of IL-1 |
T11618 |
22810-22828 |
Protein |
denotes |
the IL-1-signaling |
T11553 |
22856-22865 |
Protein |
denotes |
by IL-1Ra |
T11502 |
22877-22883 |
Protein |
denotes |
IL-1Ra |
T11515 |
22983-23014 |
Protein |
denotes |
Intracellular IL-1Ra (icIL-1Ra) |
T11506 |
23005-23013 |
Protein |
denotes |
icIL-1Ra |
T11527 |
23024-23028 |
Protein |
denotes |
IL-6 |
T11511 |
23033-23037 |
Protein |
denotes |
IL-8 |
T11695 |
23033-23048 |
Gene_expression |
denotes |
IL-8 production |
T11651 |
23126-23132 |
Protein |
denotes |
IL-1Ra |
T11517 |
23193-23197 |
Protein |
denotes |
mice |
T11566 |
23214-23232 |
Entity |
denotes |
B16 melanoma cells |
T11571 |
23270-23276 |
Protein |
denotes |
IL-1Ra |
T11642 |
23348-23352 |
Protein |
denotes |
mice |
T11682 |
23361-23407 |
Negative_regulation |
denotes |
the inactivation of NF-κB in the present study |
T11656 |
23378-23386 |
Protein |
denotes |
of NF-κB |
T11531 |
23409-23413 |
Protein |
denotes |
CCR5 |
T11608 |
23480-23506 |
Entity |
denotes |
of a dendrite cell vaccine |
T11593 |
23480-23506 |
Entity |
denotes |
of a dendrite cell vaccine |
T11643 |
23485-23493 |
Entity |
denotes |
dendrite |
T11621 |
23518-23522 |
Protein |
denotes |
mice |
T11615 |
23545-23554 |
Protein |
denotes |
mice [10] |
T11636 |
23573-23575 |
Protein |
denotes |
RS |
T11612 |
23596-23603 |
Protein |
denotes |
of CCR5 |
T11507 |
23714-23718 |
Protein |
denotes |
CCR5 |
T11504 |
23817-23820 |
Entity |
denotes |
Tan |
T11513 |
23817-23823 |
Protein |
denotes |
Tan MC |
T11685 |
23846-23936 |
Negative_regulation |
denotes |
disruption of CCR5/CCL5 signaling, either by reducing CCL5 production by tumor cells or by |
T11689 |
23857-23880 |
Positive_regulation |
denotes |
of CCR5/CCL5 signaling, |
T11596 |
23860-23869 |
Protein |
denotes |
CCR5/CCL5 |
T11570 |
23860-23869 |
Protein |
denotes |
CCR5/CCL5 |
T11539 |
23865-23869 |
Protein |
denotes |
CCL5 |
T11677 |
23891-23930 |
Negative_regulation |
denotes |
reducing CCL5 production by tumor cells |
T11526 |
23900-23904 |
Protein |
denotes |
CCL5 |
T11681 |
23900-23915 |
Gene_expression |
denotes |
CCL5 production |
T11530 |
23919-23930 |
Entity |
denotes |
tumor cells |
T11497 |
23966-23970 |
Protein |
denotes |
CCR5 |
T11641 |
23966-23980 |
Entity |
denotes |
CCR5 inhibitor |
T11575 |
23992-24004 |
Entity |
denotes |
reduced Treg |
T11540 |
24006-24024 |
Entity |
denotes |
regulatory T cells |
T11555 |
24076-24092 |
Protein |
denotes |
control mice [9] |
T11565 |
24170-24182 |
Protein |
denotes |
CCR5−/− mice |
T11581 |
24289-24293 |
Protein |
denotes |
mice |
T11640 |
24354-24374 |
Entity |
denotes |
of cytotoxic T cells |
T11521 |
24376-24379 |
Protein |
denotes |
CD8 |
T11647 |
24380-24408 |
Entity |
denotes |
positive T Lymphocytes cells |
T11558 |
24380-24408 |
Entity |
denotes |
positive T Lymphocytes cells |
T11563 |
24414-24434 |
Entity |
denotes |
natural killer cells |
T11578 |
24441-24458 |
Entity |
denotes |
positive NK cells |
T11567 |
24472-24480 |
Entity |
denotes |
dendrite |
T11568 |
24472-24486 |
Entity |
denotes |
dendrite cells |
T11583 |
24532-24546 |
Entity |
denotes |
melanoma cells |
T11665 |
24552-24587 |
Entity |
denotes |
the lymphocytes of the CCR5−/− mice |
T11597 |
24571-24587 |
Protein |
denotes |
the CCR5−/− mice |
T11590 |
24624-24638 |
Entity |
denotes |
melanoma cells |
T11576 |
24689-24705 |
Protein |
denotes |
the CCR5+/+ mice |
T11653 |
24710-24727 |
Protein |
denotes |
the CCR5−/− mice, |
T11520 |
24841-24871 |
Protein |
denotes |
the cytokine array experiment, |
T11595 |
24885-24891 |
Protein |
denotes |
MIP-1α |
T11630 |
24924-24930 |
Entity |
denotes |
T cell |
T11666 |
24957-25026 |
Protein |
denotes |
increased in the CCR5−/− mice compared with those in the CCR5+/+ mice |
T11538 |
25010-25026 |
Protein |
denotes |
the CCR5+/+ mice |
T11645 |
25034-25093 |
Entity |
denotes |
relatively increased tumor associated cytotoxic lymphocytes |
T11552 |
25072-25081 |
Entity |
denotes |
cytotoxic |
T11532 |
25163-25169 |
Protein |
denotes |
− mice |
T11691 |
25171-25190 |
Positive_regulation |
denotes |
Activation of NF-κB |
T11664 |
25182-25190 |
Protein |
denotes |
of NF-κB |
T11627 |
25231-25242 |
Entity |
denotes |
of NK cells |
T11692 |
25266-25294 |
Negative_regulation |
denotes |
Inhibition of NF-κB activity |
T11579 |
25280-25285 |
Protein |
denotes |
NF-κB |
T11518 |
25305-25312 |
Entity |
denotes |
NK cell |
T11549 |
25377-25381 |
Protein |
denotes |
IL-6 |
T11544 |
25405-25424 |
Protein |
denotes |
the decreased NF-κB |
T11534 |
25429-25444 |
Protein |
denotes |
elevated IL-1Ra |
T11559 |
25490-25514 |
Entity |
denotes |
of cytotoxic lymphocytes |
T11582 |
25493-25502 |
Entity |
denotes |
cytotoxic |
T11639 |
25578-25619 |
Protein |
denotes |
IL-23, a tumor growth promoting cytokine, |
T11512 |
25610-25618 |
Protein |
denotes |
cytokine |
T11509 |
25630-25635 |
Protein |
denotes |
NF-κB |
T11528 |
25647-25651 |
Entity |
denotes |
cell |
T11591 |
25710-25715 |
Protein |
denotes |
NF-κB |
T11601 |
25737-25749 |
Protein |
denotes |
the cytokine |
T11585 |
25781-25796 |
Entity |
denotes |
of immune cells |
T11619 |
25825-25831 |
Protein |
denotes |
IL-1Ra |
T11588 |
25889-25916 |
Entity |
denotes |
of myeloid suppressor cells |
T11663 |
25994-25999 |
Protein |
denotes |
IL-1α |
T11580 |
25994-26014 |
Protein |
denotes |
IL-1α knockout mice, |
T11611 |
26032-26038 |
Protein |
denotes |
IL-1Ra |
T11535 |
26032-26043 |
Protein |
denotes |
IL-1Ra mice |
T11609 |
26072-26083 |
Entity |
denotes |
of NK cells |
T11533 |
26152-26160 |
Protein |
denotes |
of NF-κB |
T11510 |
26180-26189 |
Protein |
denotes |
of IL-1Ra |
T11660 |
26249-26253 |
Protein |
denotes |
mice |
T11648 |
26308-26315 |
Protein |
denotes |
of CCR5 |
T11633 |
26325-26329 |
Protein |
denotes |
CCR5 |
T11556 |
26333-26361 |
Protein |
denotes |
a G protein–coupled receptor |
T11572 |
26391-26434 |
Entity |
denotes |
a small molecule for the inhibition of CCR5 |
T11678 |
26412-26434 |
Negative_regulation |
denotes |
the inhibition of CCR5 |
T11508 |
26427-26434 |
Protein |
denotes |
of CCR5 |
T11561 |
26576-26580 |
Protein |
denotes |
CCR5 |
T11498 |
26674-26695 |
Entity |
denotes |
melanoma cells growth |
T11548 |
26725-26749 |
Protein |
denotes |
of NF-κB/IL-1Ra pathways |
T11514 |
26734-26740 |
Protein |
denotes |
IL-1Ra |
T11599 |
26761-26765 |
Protein |
denotes |
mice |
T13587 |
27002-27030 |
Protein |
denotes |
The CCR5 wild type (CCR5+/+) |
T13582 |
27035-27039 |
Protein |
denotes |
CCR5 |
T13588 |
27059-27063 |
Protein |
denotes |
mice |
T13585 |
27138-27146 |
Protein |
denotes |
The mice |
T13576 |
27289-27310 |
Protein |
denotes |
The mice (n = 4/cage) |
T13581 |
27305-27309 |
Protein |
denotes |
cage |
T13580 |
27513-27529 |
Protein |
denotes |
The CCR5+/+ mice |
T13579 |
27531-27535 |
Entity |
denotes |
n = |
T13589 |
27543-27555 |
Protein |
denotes |
CCR5−/− mice |
T13574 |
27557-27561 |
Entity |
denotes |
n = |
T13575 |
27671-27673 |
Protein |
denotes |
F2 |
T13578 |
27671-27737 |
Protein |
denotes |
F2 hybrid mice from the C57BL/6J-AW-J and 129P3/J parental strains |
T13584 |
27739-27743 |
Protein |
denotes |
CCR5 |
T13577 |
27739-27748 |
Protein |
denotes |
CCR5 mice |
T13590 |
27804-27855 |
Regulation |
denotes |
of the CCR5 gene deleted from the parental strains, |
T13583 |
27804-27855 |
Protein |
denotes |
of the CCR5 gene deleted from the parental strains, |
T13586 |
27811-27815 |
Protein |
denotes |
CCR5 |
T14051 |
27943-27961 |
Entity |
denotes |
B16 melanoma cells |
T14053 |
27992-28009 |
Entity |
denotes |
5×105 tumor cells |
T14055 |
28013-28029 |
Entity |
denotes |
0.1 ml Phosphate |
T14052 |
28039-28050 |
Entity |
denotes |
saline(PBS) |
T14054 |
28107-28126 |
Protein |
denotes |
of the carrier mice |
T14405 |
28585-28652 |
Negative_regulation |
denotes |
with protein extraction solution (PRO-PREPTM, Intron Biotechnology, |
T14386 |
28590-28597 |
Protein |
denotes |
protein |
T14393 |
28631-28651 |
Entity |
denotes |
Intron Biotechnology |
T14403 |
28672-28683 |
Protein |
denotes |
lysed by 60 |
T14385 |
28702-28705 |
Entity |
denotes |
ice |
T14377 |
28784-28803 |
Protein |
denotes |
of proteins (40 µg) |
T14389 |
28822-28851 |
Entity |
denotes |
a SDS/12%-polyacrylamide gel, |
T14383 |
28822-28851 |
Entity |
denotes |
a SDS/12%-polyacrylamide gel, |
T14390 |
28824-28827 |
Protein |
denotes |
SDS |
T14404 |
28876-28910 |
Entity |
denotes |
a polyvinylidene difluoride (PVDF) |
T14373 |
28905-28909 |
Entity |
denotes |
PVDF |
T14398 |
28911-28955 |
Entity |
denotes |
membrane (GE Water and Process technologies, |
T14369 |
28965-28967 |
Protein |
denotes |
PA |
T14384 |
28998-29054 |
Entity |
denotes |
1 h at room temperature with 5% (w/v) non-fat dried milk |
T14397 |
29027-29054 |
Entity |
denotes |
5% (w/v) non-fat dried milk |
T14399 |
29095-29105 |
Entity |
denotes |
10 mM Tris |
T14370 |
29119-29156 |
Entity |
denotes |
150 mM NaCl solution containing 0.05% |
T14387 |
29126-29130 |
Entity |
denotes |
NaCl |
T14381 |
29199-29212 |
Entity |
denotes |
the membranes |
T14388 |
29251-29298 |
Entity |
denotes |
primary antibodies: mouse monoclonal antibodies |
T14372 |
29251-29298 |
Entity |
denotes |
primary antibodies: mouse monoclonal antibodies |
T14395 |
29271-29298 |
Protein |
denotes |
mouse monoclonal antibodies |
T14380 |
29316-29319 |
Protein |
denotes |
p65 |
T14396 |
29324-29327 |
Protein |
denotes |
p50 |
T14375 |
29346-29351 |
Entity |
denotes |
Santa |
T14378 |
29396-29447 |
Entity |
denotes |
polyclonal antibodies directed against Bax and PARP |
T14371 |
29435-29438 |
Protein |
denotes |
Bax |
T14382 |
29443-29447 |
Protein |
denotes |
PARP |
T14392 |
29466-29471 |
Entity |
denotes |
Santa |
T14402 |
29505-29514 |
Protein |
denotes |
caspase-3 |
T14379 |
29516-29525 |
Protein |
denotes |
caspase-9 |
T14368 |
29527-29532 |
Protein |
denotes |
Bcl-2 |
T14401 |
29537-29544 |
Protein |
denotes |
c-IAP-1 |
T14400 |
29564-29568 |
Entity |
denotes |
Cell |
T14394 |
29600-29602 |
Protein |
denotes |
MA |
T14374 |
29662-29672 |
Protein |
denotes |
peroxidase |
T14391 |
29760-29783 |
Protein |
denotes |
Immunoreactive proteins |
T14376 |
29807-29810 |
Protein |
denotes |
ECL |
T15409 |
29879-29887 |
Entity |
denotes |
formalin |
T15391 |
29904-29912 |
Entity |
denotes |
paraffin |
T15401 |
30016-30033 |
Entity |
denotes |
paraffin-embedded |
T15411 |
30110-30159 |
Binding |
denotes |
then subjected to heat-mediated antigen retrieval |
T15398 |
30142-30149 |
Entity |
denotes |
antigen |
T15386 |
30172-30182 |
Protein |
denotes |
peroxidase |
T15378 |
30222-30254 |
Entity |
denotes |
3% hydrogen peroxide in methanol |
T15381 |
30246-30254 |
Entity |
denotes |
methanol |
T15385 |
30453-30486 |
Entity |
denotes |
cell nuclear antigen (PCNA, 1∶200 |
T15406 |
30458-30480 |
Protein |
denotes |
nuclear antigen (PCNA, |
T15382 |
30475-30479 |
Protein |
denotes |
PCNA |
T15408 |
30487-30495 |
Entity |
denotes |
dilution |
T15405 |
30497-30518 |
Protein |
denotes |
monoclonal antibodies |
T15400 |
30541-30544 |
Entity |
denotes |
4 h |
T15387 |
30694-30704 |
Entity |
denotes |
antibodies |
T15379 |
30711-30712 |
Entity |
denotes |
h |
T15407 |
30770-30809 |
Protein |
denotes |
of the avidin biotin peroxidase complex |
T15404 |
30770-30809 |
Entity |
denotes |
of the avidin biotin peroxidase complex |
T15396 |
30770-30809 |
Entity |
denotes |
of the avidin biotin peroxidase complex |
T15383 |
30791-30801 |
Protein |
denotes |
peroxidase |
T15394 |
30894-30904 |
Protein |
denotes |
peroxidase |
T15403 |
30960-30969 |
Entity |
denotes |
peroxide, |
T15395 |
31003-31014 |
Entity |
denotes |
hematoxylin |
T15380 |
31028-31032 |
Entity |
denotes |
aqua |
T15412 |
31124-31207 |
Positive_regulation |
denotes |
A negative control was included in all experiments by omitting the primary antibody |
T15397 |
31187-31207 |
Entity |
denotes |
the primary antibody |
T15389 |
31277-31294 |
Entity |
denotes |
paraffin-embedded |
T15390 |
31322-31393 |
Entity |
denotes |
a mixture of the labeling solution (540 µl) and enzyme solution (60 µl) |
T15384 |
31335-31365 |
Entity |
denotes |
the labeling solution (540 µl) |
T15399 |
31370-31376 |
Protein |
denotes |
enzyme |
T15410 |
31370-31393 |
Entity |
denotes |
enzyme solution (60 µl) |
T15393 |
31398-31410 |
Entity |
denotes |
1 h at 37°C, |
T15402 |
31568-31589 |
Entity |
denotes |
2-phenylindole (DAPI) |
T15392 |
31584-31588 |
Entity |
denotes |
DAPI |
T15388 |
31711-31714 |
Entity |
denotes |
DAS |
T15682 |
32436-32439 |
Protein |
denotes |
Apo |
T16156 |
32490-32521 |
Entity |
denotes |
Gel Electromobility Shift Assay |
T16168 |
32522-32549 |
Entity |
denotes |
A gel electromobility shift |
T16177 |
32702-32713 |
Entity |
denotes |
of solution |
T16174 |
32717-32737 |
Entity |
denotes |
10 mM HEPES [pH 7.9] |
T16163 |
32746-32763 |
Entity |
denotes |
MgCl2, 10 mM KCl, |
T16165 |
32753-32762 |
Entity |
denotes |
10 mM KCl |
T16167 |
32764-32823 |
Entity |
denotes |
0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonylfluoride) |
T16164 |
32787-32822 |
Entity |
denotes |
0.2 mM phenylmethylsulfonylfluoride |
T16179 |
32825-32833 |
Entity |
denotes |
vortexed |
T16159 |
32859-32862 |
Entity |
denotes |
ice |
T16181 |
32921-32940 |
Entity |
denotes |
The pelleted nuclei |
T16169 |
32961-33031 |
Entity |
denotes |
solution C (solution A supplemented with 420 mM NaCl and 20% glycerol) |
T16160 |
33002-33013 |
Entity |
denotes |
420 mM NaCl |
T16162 |
33018-33030 |
Entity |
denotes |
20% glycerol |
T16182 |
33047-33060 |
Entity |
denotes |
on ice for 20 |
T16180 |
33134-33176 |
Entity |
denotes |
the resulting nuclear extracts supernatant |
T16155 |
33195-33219 |
Protein |
denotes |
a chilled Eppendorf tube |
T16172 |
33221-33247 |
Entity |
denotes |
Consensus oligonucleotides |
T16176 |
33253-33295 |
Protein |
denotes |
end-labeled using T4 polynucleotide kinase |
T16173 |
33271-33273 |
Entity |
denotes |
T4 |
T16170 |
33301-33304 |
Entity |
denotes |
P32 |
T16157 |
33305-33320 |
Entity |
denotes |
-ATP for 10 min |
T16175 |
33330-33353 |
Entity |
denotes |
The gel shift reactions |
T16161 |
33426-33513 |
Entity |
denotes |
gel loading buffer was added to each reaction and loaded onto a 6% non-denaturating gel |
T16154 |
33488-33513 |
Entity |
denotes |
a 6% non-denaturating gel |
T16178 |
33515-33522 |
Entity |
denotes |
The gel |
T16171 |
33602-33609 |
Entity |
denotes |
the gel |
T16166 |
33611-33618 |
Entity |
denotes |
The gel |
T16158 |
33633-33636 |
Entity |
denotes |
1 h |
T16704 |
33711-33722 |
Entity |
denotes |
Lymphocytes |
T16721 |
33711-33789 |
Binding |
denotes |
Lymphocytes were obtained from tumor and spleen tissues for phenotype analysis |
T16717 |
33802-33819 |
Entity |
denotes |
tumor lymphocytes |
T16709 |
33891-33895 |
Protein |
denotes |
mice |
T16719 |
33989-34009 |
Entity |
denotes |
100 µm cell strainer |
T16715 |
34059-34084 |
Protein |
denotes |
ACK lysing buffer, LONZA) |
T16700 |
34063-34069 |
Protein |
denotes |
lysing |
T16710 |
34095-34110 |
Entity |
denotes |
red blood cells |
T16699 |
34112-34135 |
Entity |
denotes |
One million splenocytes |
T16706 |
34171-34200 |
Protein |
denotes |
1% bovine serum albumin (BSA) |
T16716 |
34196-34199 |
Protein |
denotes |
BSA |
T16707 |
34235-34238 |
Protein |
denotes |
BSA |
T16722 |
34258-34303 |
Binding |
denotes |
one million cells obtained from tumor tissues |
T16696 |
34258-34303 |
Entity |
denotes |
one million cells obtained from tumor tissues |
T16720 |
34345-34386 |
Binding |
denotes |
obtain suspension cell for 1hour at 37°C, |
T16711 |
34352-34367 |
Entity |
denotes |
suspension cell |
T16703 |
34352-34367 |
Entity |
denotes |
suspension cell |
T16712 |
34447-34462 |
Entity |
denotes |
the lymphocytes |
T16714 |
34502-34524 |
Protein |
denotes |
monoclonal antibodies, |
T16698 |
34535-34542 |
Protein |
denotes |
CD4-APC |
T16695 |
34535-34542 |
Entity |
denotes |
CD4-APC |
T16701 |
34544-34552 |
Entity |
denotes |
CD8-FITC |
T16697 |
34544-34552 |
Protein |
denotes |
CD8-FITC |
T16713 |
34683-34725 |
Protein |
denotes |
a FACSAria flow cytometry (BD Biosciences) |
T16702 |
34689-34693 |
Protein |
denotes |
Aria |
T16708 |
34793-34810 |
Protein |
denotes |
Scripps, La Jolla |
T16718 |
34863-34890 |
Entity |
denotes |
used to gate on lymphocytes |
T16705 |
34871-34875 |
Entity |
denotes |
gate |
T16954 |
34893-34914 |
Entity |
denotes |
Protein Immuno-arrays |
T16956 |
34985-34993 |
Protein |
denotes |
protease |
T16961 |
34985-35033 |
Entity |
denotes |
protease inhibitor cocktail (Sigma-Aldrich, USA) |
T16960 |
35014-35019 |
Protein |
denotes |
Sigma |
T16959 |
35038-35075 |
Entity |
denotes |
Triton X-100 (final concentration 1%) |
T16958 |
35218-35231 |
Protein |
denotes |
protein assay |
T16957 |
35283-35332 |
Protein |
denotes |
proteins, collected from three samples per group, |
T16955 |
35347-35367 |
Protein |
denotes |
Mouse cytokine array |
T17078 |
35551-35554 |
Protein |
denotes |
Pad |
T17076 |
35565-35567 |
Protein |
denotes |
La |
T17077 |
35640-35644 |
Protein |
denotes |
mice |
T17080 |
35649-35661 |
Protein |
denotes |
CCR5+/+ mice |
T17079 |
35682-35683 |
Entity |
denotes |
t |
T17075 |
35861-35871 |
Protein |
denotes |
Mantel-Cox |
T17074 |
35881-35895 |
Protein |
denotes |
GraphPad Prism |
R12778 |
T17673 |
T17687 |
themeOf |
of proliferating cell nuclear antigen (PCNA),expression of proliferating cell nuclear antigen (PCNA) |
R13081 |
T18149 |
T18163 |
themeOf |
p65,"p65 phosphorylation in nuclear extracts (NE)," |
R13082 |
T18152 |
T18161 |
themeOf |
NF-κB,Decrease of NF-κB Activity in Tumor Tissue of CCR5−/− |
R13083 |
T18158 |
T18162 |
themeOf |
of p50,Expression of p50 |
R13302 |
T18530 |
T18554 |
themeOf |
of apoptotic proteins,The expression of apoptotic proteins |
R13303 |
T18545 |
T18555 |
themeOf |
tumor tissues of CCR5 −/− mice,tumor tissues of CCR5 −/− mice |
R13800 |
T19267 |
T19297 |
themeOf |
cytokine,the cytokine expression difference in tumor tissues of CCR5+/+ mice and CCR5−/− |
R13801 |
T19272 |
T19296 |
themeOf |
of IL-1Ra,Expression of IL-1Ra was analyzed by western blotting in tumor and spleen tissues |
R13802 |
T19293 |
T19295 |
themeOf |
of IL-1Ra,Upregulation of IL-1Ra in the Tumor and Spleen of CCR5− |
R3033 |
T4231 |
T4341 |
themeOf |
IL-1,inhibit IL-1 |
R3036 |
T4235 |
T4351 |
themeOf |
IL-1Ra,IL-1Ra expression |
R3038 |
T4239 |
T4350 |
causeOf |
(3) increasing the production of tumor killing lymphokines,(3) increasing the production of tumor killing lymphokines |
R3041 |
T4243 |
T4360 |
themeOf |
of tumor killing lymphokines,the production of tumor killing lymphokines |
R3044 |
T4248 |
T4340 |
themeOf |
of the CCL5,Local production of the CCL5 |
R3045 |
T4249 |
T4348 |
themeOf |
of IL-1Ra,the expression of IL-1Ra |
R3051 |
T4279 |
T4342 |
themeOf |
IFNγ,IFNγ expression |
R3052 |
T4269 |
T4358 |
themeOf |
NF-κB,blocking NF-κB |
R3053 |
T4281 |
T4353 |
themeOf |
CCR5,Intermediate and strong CCR5 expression |
R3054 |
T4288 |
T4343 |
themeOf |
CCR5,of CCR5 expression |
R3055 |
T4289 |
T4355 |
themeOf |
IL-1Ra,of IL-1Ra gene expression |
R3056 |
T4296 |
T4359 |
themeOf |
NF-κB,of NF-κB activation [38] |
R3057 |
T4298 |
T4354 |
causeOf |
a naturally occurring cytokine that competitively blocks the IL-1 receptor [13],a naturally occurring cytokine that competitively blocks the IL-1 receptor [13] |
R3058 |
T4300 |
T4361 |
themeOf |
of NF-κB,inhibition of NF-κB |
R3059 |
T4313 |
T4357 |
themeOf |
of NF-κB,Activation of NF-κB |
R3060 |
T4320 |
T4339 |
themeOf |
of NF-κB,that inhibition of NF-κB by dehydroxymethyl-epoxyquinomicin (DHMEQ) |
R3061 |
T4328 |
T4354 |
themeOf |
the IL-1 receptor [13],a naturally occurring cytokine that competitively blocks the IL-1 receptor [13] |
R3062 |
T4330 |
T4346 |
themeOf |
in CCR5 mediated tumor development,in CCR5 mediated tumor development |
R3063 |
T4333 |
T4362 |
themeOf |
CCR5,CCR5 disruption |
R3064 |
T4334 |
T4339 |
causeOf |
by dehydroxymethyl-epoxyquinomicin (DHMEQ),that inhibition of NF-κB by dehydroxymethyl-epoxyquinomicin (DHMEQ) |
R3065 |
T4336 |
T4344 |
themeOf |
of NF-κB,Activation of NF-κB |
R3066 |
T4343 |
T4347 |
themeOf |
of CCR5 expression,inhibition of CCR5 expression [32] |
R3067 |
T4351 |
T4345 |
themeOf |
IL-1Ra expression,"IL-1Ra expression was reduced in prostate [14], breast [15], and skin cancer [16]" |
R3068 |
T4355 |
T4352 |
themeOf |
of IL-1Ra gene expression,the regulation of IL-1Ra gene expression |
R3069 |
T4360 |
T4350 |
themeOf |
the production of tumor killing lymphokines,(3) increasing the production of tumor killing lymphokines |
R4050 |
T5887 |
T5900 |
themeOf |
CCR5,CCR5 expression |
R4051 |
T5892 |
T5899 |
themeOf |
of NF-κB,The activation of NF-κB |
R4052 |
T5893 |
T5902 |
themeOf |
NF-κB,Decrease of NF-κB Activity in Tumor Tissue of CCR5−/− |
R4053 |
T5897 |
T5903 |
themeOf |
of NF-κB,the inactivation of NF-κB in melanoma |
R419 |
T778 |
T817 |
themeOf |
"of genes involving cell growth, apoptosis, and tumor growth","the regulation of genes involving cell growth, apoptosis, and tumor growth" |
R420 |
T779 |
T818 |
themeOf |
of IL-1Ra,Upregulation of IL-1Ra in Melanoma Model |
R421 |
T795 |
T819 |
themeOf |
"cleaved caspase-3, cleaved PARP,","cleaved caspase-3, cleaved PARP," |
R422 |
T797 |
T814 |
themeOf |
of NF-κB,We investigated the activation of NF-κB since it is an implicated transcription |
R423 |
T807 |
T815 |
themeOf |
of IL-1Ra,upregulation of IL-1Ra |
R424 |
T813 |
T816 |
themeOf |
protein,protein expression |
R4353 |
T6398 |
T6414 |
themeOf |
of apoptotic cell death regulatory proteins,expression of apoptotic cell death regulatory proteins |
R4354 |
T6410 |
T6412 |
themeOf |
the tumor tissues of the CCR5−/− mice,the tumor tissues of the CCR5−/− mice |
R4909 |
T7215 |
T7228 |
themeOf |
of IL-1Ra,The expression of IL-1Ra |
R4910 |
T7216 |
T7226 |
themeOf |
of IL-1Ra,the expression of IL-1Ra in tumor and spleen tissues was analyzed by immunofluorescence and western |
R4911 |
T7223 |
T7227 |
themeOf |
of IL-1Ra,Upregulation of IL-1Ra in the Tumor and Spleen of CCR5−/− Mice |
R4912 |
T7228 |
T7225 |
themeOf |
The expression of IL-1Ra,The expression of IL-1Ra was upregulated in tumor and spleen tissues of the CCR5−/− |
R5871 |
T8618 |
T8670 |
themeOf |
"− mice in immunity-related organ,","− mice in immunity-related organ," |
R7549 |
T11499 |
T11674 |
causeOf |
IL-1,IL-1 signaling |
R7553 |
T11508 |
T11678 |
themeOf |
of CCR5,the inhibition of CCR5 |
R7557 |
T11511 |
T11695 |
themeOf |
IL-8,IL-8 production |
R7559 |
T11526 |
T11681 |
themeOf |
CCL5,CCL5 production |
R7561 |
T11550 |
T11688 |
themeOf |
of NF-κB,the expression of NF-κB |
R7562 |
T11622 |
T11676 |
themeOf |
constitutively activated NF-κB,constitutively activated NF-κB |
R7563 |
T11629 |
T11690 |
themeOf |
of NF-κB,the activation of NF-κB |
R7564 |
T11554 |
T11693 |
themeOf |
"of cell death inhibitory NF-κB target genes, such as Bcl-2 and cIAP","the expression of cell death inhibitory NF-κB target genes, such as Bcl-2 and cIAP" |
R7565 |
T11631 |
T11669 |
causeOf |
NF-κB,"NF-κB regulates the expression of over 200 genes that control the immune system, cancer cell growth and inflammation [39]" |
R7566 |
T11635 |
T11675 |
themeOf |
of target genes,the expression of target genes |
R7567 |
T11560 |
T11686 |
themeOf |
"the melanoma tumor tissues of the CCR5−/− mice,","the melanoma tumor tissues of the CCR5−/− mice," |
R7568 |
T11637 |
T11683 |
themeOf |
of NF-κB,Inhibition of NF-κB by the IL-10 |
R7569 |
T11638 |
T11694 |
causeOf |
by many cytokines,that NF-κB is activated or inactivated by many cytokines |
R7570 |
T11564 |
T11684 |
themeOf |
NF-κB,regulating NF-κB |
R7571 |
T11569 |
T11679 |
causeOf |
IL-1,of IL-1 signaling |
R7572 |
T11654 |
T11687 |
causeOf |
IL-1,"IL-1 induces the activation of NF-κB in several cancers, and increases cell cycle progression" |
R7573 |
T11596 |
T11689 |
causeOf |
CCR5/CCL5,"of CCR5/CCL5 signaling," |
R7574 |
T11656 |
T11682 |
themeOf |
of NF-κB,the inactivation of NF-κB in the present study |
R7575 |
T11657 |
T11670 |
themeOf |
activated NF-κB,activated NF-κB |
R7576 |
T11664 |
T11691 |
themeOf |
of NF-κB,Activation of NF-κB |
R7577 |
T11671 |
T11669 |
themeOf |
"the expression of over 200 genes that control the immune system, cancer cell growth and inflammation [39]","NF-κB regulates the expression of over 200 genes that control the immune system, cancer cell growth and inflammation [39]" |
R7578 |
T11679 |
T11673 |
themeOf |
of IL-1 signaling,dysregulation of IL-1 signaling |
R7579 |
T11598 |
T11683 |
causeOf |
by the IL-10,Inhibition of NF-κB by the IL-10 |
R7580 |
T11681 |
T11677 |
themeOf |
CCL5 production,reducing CCL5 production by tumor cells |
R7581 |
T11600 |
T11671 |
themeOf |
"of over 200 genes that control the immune system, cancer cell growth and inflammation [39]","the expression of over 200 genes that control the immune system, cancer cell growth and inflammation [39]" |
R7582 |
T11602 |
T11680 |
themeOf |
of IL-1Ra,"The elevated expression of IL-1Ra, without any change of IL-1" |
R7583 |
T11689 |
T11685 |
themeOf |
"of CCR5/CCL5 signaling,","disruption of CCR5/CCL5 signaling, either by reducing CCL5 production by tumor cells or by" |
R7584 |
T11603 |
T11672 |
themeOf |
NF-κB,that NF-κB is activated or inactivated by many cytokines |
R7585 |
T11603 |
T11694 |
themeOf |
NF-κB,that NF-κB is activated or inactivated by many cytokines |
R9291 |
T13583 |
T13590 |
themeOf |
"of the CCR5 gene deleted from the parental strains,","of the CCR5 gene deleted from the parental strains," |
R9971 |
T14386 |
T14405 |
themeOf |
protein,"with protein extraction solution (PRO-PREPTM, Intron Biotechnology," |